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abstract
PURPOSE The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may
contribute to antitumor activity when combined with programmed death receptor-1 (PD-1) signaling inhibitors in
hepatocellular carcinoma (HCC). We report results from a phase Ib study of lenvatinib plus pembrolizumab (an
anti–PD-1 antibody) in unresectable HCC (uHCC).
PATIENTS AND METHODS In this open-label multicenter study, patients with uHCC received lenvatinib (body-
weight$ 60 kg, 12 mg;, 60 kg, 8 mg) orally daily and pembrolizumab 200 mg intravenously on day 1 of a 21-
day cycle. The study included a dose-limiting toxicity (DLT) phase and an expansion phase (first-line patients).
Primary objectives were safety/tolerability (DLT phase), and objective response rate (ORR) and duration of
response (DOR) bymodified RECIST (mRECIST) and RECIST version 1.1 (v1.1) per independent imaging review
(IIR; expansion phase).
RESULTS A total of 104 patients were enrolled. No DLTs were reported (n 5 6) in the DLT phase; 100 patients
(expansion phase; included n5 2 from DLT phase) had received no prior systemic therapy and had Barcelona
Clinic Liver Cancer stage B (n 5 29) or C disease (n 5 71). At data cutoff, 37% of patients remained on
treatment. Median duration of follow-up was 10.6 months (95% CI, 9.2 to 11.5 months). Confirmed ORRs by IIR
were 46.0% (95% CI, 36.0% to 56.3%) per mRECIST and 36.0% (95% CI, 26.6% to 46.2%) per RECIST v1.1.
Median DORs by IIR were 8.6 months (95% CI, 6.9 months to not estimable [NE]) per mRECIST and
12.6 months (95% CI, 6.9 months to NE) per RECIST v1.1. Median progression-free survival by IIR was
9.3 months per mRECIST and 8.6 months per RECIST v1.1. Median overall survival was 22 months. Grade
$ 3 treatment-related adverse events occurred in 67% (grade 5, 3%) of patients. No new safety signals were
identified.
CONCLUSION Lenvatinib plus pembrolizumab has promising antitumor activity in uHCC. Toxicities were
manageable, with no unexpected safety signals.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is estimated to be the
sixth most prevalent cancer worldwide and the fourth
leading cause of cancer-related death.1 Despite ad-
vances in early detection, a majority of patients with
HCC present with advanced disease.2
Patients with advancedHCC or tumor progression after
locoregional treatment can benefit from systemic
treatment.3 Sorafenib demonstrated a statistically
significant survival benefit versus placebo in 2 ran-
domized phase III studies in advanced HCC (SHARP
study4 and Asia-Pacific study5). Lenvatinib, a multi-
kinase inhibitor of vascular endothelial growth factor
(VEGF) receptors 1 to 3, fibroblast growth factor (FGF)
receptors 1 to 4, platelet-derived growth factor receptor-a
(PDGFRa), RET, and KIT,6-9 was later approved for
first-line treatment of unresectable HCC (uHCC) based
on the phase III REFLECT study.10 In REFLECT, len-
vatinib met its primary end point of overall survival
(OS) by statistical confirmation of noninferiority to
sorafenib (median OS, 13.6 months with lenvatinib v
12.3 months with sorafenib; hazard ratio [HR], 0.92;
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significant and clinically meaningful improvements versus
sorafenib in objective response rate (ORR; including un-
confirmed responses), progression-free survival (PFS), and
time to progression (TTP).10 Specifically, ORR by blinded
independent imaging review (IIR) was significantly higher
with lenvatinib versus sorafenib per RECIST version 1.1
(RECIST v1.1; 18.8% v 6.5%; P , .0001) and modified
RECIST11 (mRECIST; 40.6% v 12.4%; P , .0001).10 PFS
(by IIR per RECIST v1.1 and mRECIST) was also signifi-
cantly longer with lenvatinib versus sorafenib (median PFS,
7.3 v 3.6 months; P , .0001 for both RECIST v1.1 and
mRECIST).10
Immunotherapies, including immune checkpoint inhibitors,
have had promising results in patients with advanced HCC,
likely in part because of the contribution of both in-
flammation and suppressed immune microenvironments to
the pathogenesis of HCC.12,13 The potential importance of
programmed death receptor-1 (PD-1)/PD-1 ligand (PD-L1)
blockade in HCC has been further underscored by the US
Food and Drug Administration (FDA) decision to grant
accelerated approvals of pembrolizumab and nivolumab
(PD-1 monoclonal antibodies) for second-line HCC treat-
ment after the results of phase II studies.14-17 The approvals
of pembrolizumab and nivolumab were based on the
therapeutic benefits of each drug (observed by ORR and
duration of response [DOR]) in their respective phase II
studies (CheckMate-040 for nivolumab; KEYNOTE-224 for
pembrolizumab).14-17 In KEYNOTE-240, a phase III study
evaluating pembrolizumab versus placebo as a second-line
treatment option for HCC, pembrolizumab reduced the risk
of death by 22% and improved PFS versus placebo; how-
ever, pembrolizumab did not reach its primary end points (ie,
OS and PFS did not reach statistical significance per pre-
specified criteria).18
Combination therapies involving PD-1 inhibitors are being
studied for a variety of malignancies, including non–small-
cell lung cancer, renal cell carcinoma, and endometrial
cancer.19,20 In March 2020, the FDA granted ipilimumab
plus nivolumab accelerated approval as a second-line
treatment option for HCC.16,21 In addition, the combination
of lenvatinib plus pembrolizumab was granted accelerated
approval for the treatment of patients with advanced endo-
metrial carcinoma that is not microsatellite instability high or
mismatch repair deficient, who have disease progression
after systemic therapy, and who are not candidates for cu-
rative surgery or radiotherapy.15,22 The rationale for com-
bining lenvatinib with pembrolizumab is based on the ability
of lenvatinib to inhibit the proneoangiogenic and immuno-
suppressive effects of tumor microenvironments; such in-
hibition would improve the clinical benefit of PD-1 antibodies
by boosting the antitumor immune response.23,24 Preclinical
data have suggested that this combinationmay be effective in
HCC; in a mouse model of HCC, lenvatinib combined with
PD-1 signaling blockade resulted in promising antitumor
activity compared with either monotherapy.25 Specifically, in
a Hepa1-6 mouse HCC syngeneic tumor model, lenvatinib
alone decreased proportions of monocytes and macro-
phages, and in combination with a PD-1 antibody, lenvatinib
increased the percentage of early-activated CD81 T cells.25
These encouraging results led to the phase Ib study,
which was conducted to assess the tolerability, safety, and
efficacy profiles of lenvatinib plus pembrolizumab in uHCC,
reported here.
PATIENTS AND METHODS
Study Design and Participants
Study 116 is an ongoing phase Ib multicenter open-label
study of lenvatinib plus pembrolizumab in patients with
uHCC. The study consists of 2 phases: a dose-limiting
toxicity (DLT) phase and an expansion phase. Patients
received lenvatinib 12 mg (if bodyweight $ 60 kg) or 8 mg
(if bodyweight , 60 kg) orally once daily and pem-
brolizumab 200 mg intravenously on day 1 of a 21-day
treatment cycle (for up to 2 years after cycle 1 day 1). If no
DLTs were reported in the DLT phase, the expansion phase
would be initiated using the recommended dose from the
DLT phase. Treatment was continued until disease pro-
gression, development of unacceptable toxicity, or with-
drawal of consent. Additional details regarding continued
pembrolizumab treatment are provided in the Appendix
(online only).
Key inclusion criteria comprised the following: histologically
or cytologically confirmed HCC (excluding fibrolamellar,
sarcomatoid, and mixed cholangio-HCC tumors) or clini-
cally confirmed HCC according to the American Associa-
tion for the Study of Liver Diseases criteria; stage B (not
suitable for transarterial chemoembolization) or C catego-
rization based on the Barcelona Clinic Liver Cancer (BCLC)
staging system; at least 1 measurable target lesion
according to mRECIST per investigator assessment; Child-
Pugh class A (score, 5-6); and Eastern Cooperative On-
cology Group performance status (ECOG PS) of 0 or 1.
Patients were excluded if they had clear invasion of the bile
duct (classified clinically as a cholestatic type of HCC in
which a patient’s initial manifestation is obstructive jaun-
dice resulting from tumor thrombosis/compression/diffuse
infiltration into the biliary tract); portal vein invasion with
Vp426; prior blood-enhancing treatment (including blood
transfusion, blood products, or agents that stimulate blood
cell production [eg, granulocyte colony-stimulating factor])
within 28 days before first dose of study drugs; prior
treatment with lenvatinib or any anti–PD-1, anti–PD-L1, or
anti–PD-L2 agent; and imaging findings with HCC having
$ 50% liver occupation. Additionally, patients were ex-
cluded from the expansion phase if they had received prior
systemic therapy for uHCC.
Written informed consent was provided by all patients
before undergoing any study-specific procedures. The
study protocol was approved by the relevant institutional
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review boards/independent ethics committees, and the
study was conducted in accordance with the principles of
the Declaration of Helsinki and Good Clinical Practice
guidelines.
End Points and Clinical Assessments
Tolerability and safety of the combination regimen (the
primary objectives of the DLT phase) were initially eval-
uated by assessing DLTs during the first treatment cycle
using a 31 3 design. In the expansion phase, the primary
end points were ORR and DOR by mRECIST and RECIST
v1.1 per IIR. Tumor assessment scans were performed
every 6 weeks until week 24 and then every 9 weeks;
treatment decisions were based on mRECIST per in-
vestigator assessment. Additional information regarding
tumor assessments is included in the Appendix. Secondary
end points were ORR and DOR by investigator assessment
per mRECIST. Additional secondary end points included
TABLE 1. Baseline Demographic and Clinical Characteristics of
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, 200 61 (61)
$ 200 36 (36)
, 400 67 (67)







(continued in next column)
TABLE 1. Baseline Demographic and Clinical Characteristics of






Macroscopic vascular invasion 20 (20)
Macroscopic portal vein invasion 16 (16)
Extrahepatic sites 52 (52)
Macroscopic portal vein invasion, extrahepatic
spread, or both
62 (62)




Lymph nodes 30 (30)
Bone 10 (10)
Other 20 (20)
No. of involved disease sites per patient
1 46 (46)
2 41 (41)
$ 3 13 (13)
NOTE. Data presented as No. (%) unless otherwise indicated.
Abbreviations: AFP, alpha fetoprotein; BCLC, Barcelona Clinic Liver
Cancer; ECOG PS, Eastern Cooperative Oncology Group performance
status; HBV, hepatitis B virus; HCV, hepatitis C virus; IIR, independent
imaging review.
aData were missing for 3 patients.
bThese 2 patients had protocol deviations.
cPatients could be counted in multiple categories.
dBased on medical history.
eUnderlying liver cirrhosis of any etiology (eg, alcohol, nonalcoholic
steatohepatitis, hepatitis).
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PFS, TTP, time to response (TTR), and OS. Safety assess-
ments consisted of the monitoring and recording of adverse
events (AEs) according to Common Terminology Criteria for
Adverse Events version 4.03, laboratory evaluations, vital
signs, electrocardiograms, and echocardiograms or multi-
gated acquisition scans.
Statistical Analyses
The safety and efficacy analysis sets included all first-line
patients from the DLT phase and the expansion phase
who received at least 1 dose of study drug. A brief overview
of the expansion of enrollment and sample size estimation
can be found in the Appendix. ORR was calculated with
95% CI using the Clopper-Pearson method. DOR, PFS,
TTP, and OS were estimated using the Kaplan-Meier
method. DOR and TTR were analyzed for patients with
confirmed complete response (CR) or partial response.
Duration of follow-up was calculated by the reverse Kaplan-
Meier estimate of OS.27 All statistical analyses were per-
formed using SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
Patients
Overall, 104 patients were enrolled in the study (DLT and
expansion phases) between February 27, 2017, and April
11, 2019. The primary analysis set included 100 patients
who were treated in the first-line setting (4 patients from the
DLT phase were excluded because of prior sorafenib
treatment). At the data cutoff date (October 31, 2019), all
patients in the primary analysis set had an opportunity for
a minimum follow-up period of $ 6 months; 37 patients
(37%) were still receiving treatment (both study drugs,
n 5 34; lenvatinib only, n 5 3); 63 patients (63%) had
discontinued treatment; and 26 of the 63 patients remained
in survival follow-up (Appendix Table A1, online only).
The primary reasons for treatment discontinuation are listed
in Appendix Table A1. Data on subsequent anticancer
medications during survival follow-up are summarized in
Appendix Table A2 (online only).
Median patient age in the first-line setting was 66.5 years
(range, 47-86 years), and most patients were White (51%)
or Asian (28%). At baseline, 62% and 38% of patients had
ECOG PS of 0 and 1, respectively. BCLC stage B was noted
in 29% of patients and stage C in 71%. Child-Pugh scores
of 5, 6, and 7 were reported for 71%, 27%, and 2% of
patients, respectively. Proportions of patients with macro-
scopic portal vein invasion and extrahepatic spread at
baseline were 16% and 52%, respectively. Etiology of HCC
included hepatitis B (19%), hepatitis C (36%), and alcohol
(28%); and 30% of patients had an alpha fetoprotein level
$ 400 ng/mL (Table 1).
Study Drug Exposure
In the first-line setting, at the time of data cutoff, median
duration of exposure was 7.9 months (range, 0.2-31.1
months) for lenvatinib plus pembrolizumab (lenvatinib: me-
dian, 7.6 months; range, 0.2-31.1 months; pembrolizumab:
median, 7.4 months; range, 0.03-23.5 months). Median
received dose as a percentage of the planned starting dose of
lenvatinib was 69% (range, 23%-100%). Median number of
pembrolizumab administrations was 11 (range, 1-33
administrations).
TABLE 2. Most Common Treatment-Related AEs in Those Receiving Lenvatinib Plus Pembrolizumab (N 5 100)
Preferred AE Term
No. (%)
Any Gradeab Grade 1 Grade 2 Grade 3
Hypertension 36 (36) 1 (1) 18 (18) 17 (17)
Diarrhea 35 (35) 19 (19) 11 (11) 5 (5)
Fatigue 30 (30) 12 (12) 14 (14) 4 (4)
Decreased appetite 28 (28) 12 (12) 16 (16) 0
Hypothyroidism 25 (25) 11 (11) 14 (14) 0
Palmar-plantar erythrodysesthesia syndrome 23 (23) 13 (13) 9 (9) 1 (1)
Weight decreased 22 (22) 8 (8) 11 (11) 3 (3)
Dysphonia 21 (21) 19 (19) 1 (1) 1 (1)
AST increased 20 (20) 4 (4) 5 (5) 11 (11)
Proteinuria 20 (20) 9 (9) 7 (7) 4 (4)
Asthenia 19 (19) 4 (4) 10 (10) 5 (5)
Nausea 17 (17) 10 (10) 6 (6) 1 (1)
Rash 15 (15) 11 (11) 3 (3) 1 (1)
NOTE. Any-grade treatment-related adverse events (AEs) occurring in $ 15% of patients.
aThere were 3 grade 5 treatment-related AEs, comprising acute respiratory failure/acute respiratory distress syndrome (n 5 1), abnormal
hepatic function (n 5 1), and intestinal perforation (n 5 1), all of which are well-described potential AEs for these drug classes.
bNone of the most common treatment-related AEs (reported in this table) were grade $ 4.
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TABLE 3. Summary of Efficacy Outcomes in Those Receiving Lenvatinib Plus Pembrolizumab (N 5 100)
Parameter
mRECIST
RECIST Version 1.1 per IIRInvestigator Review IIR
ORR (confirmed responses only) 41 (41) 46 (46) 36 (36)
95% CIa 31.3 to 51.3 36.0 to 56.3 26.6 to 46.2
ORR (confirmed and unconfirmed responses) 46 (46) 53 (53) 44 (44)
95% CIa 36.0 to 56.3 42.8 to 63.1 34.1 to 54.3
Best overall response
CR 5 (5) 11 (11) 1 (1)
PR 36 (36) 35 (35) 35 (35)
SDb 45 (45) 42 (42) 52 (52)
PD 7 (7) 7 (7) 7 (7)
Unknown/not evaluable 7 (7) 5 (5) 5 (5)
DORc for confirmed responders, months
Median 12.6 8.6 12.6
95% CId 6.2 to 18.7 6.9 to NE 6.9 to NE
DORc $ 6 months 22 24 17
Probability 0.75 0.83 0.73
95% CIe 0.57 to 0.86 0.68 to 0.92 0.52 to 0.86
TTR for confirmed responders, months
Median 2.7 1.9 2.8
Range 1.2-11.8 1.2-5.5 1.2-7.7
DCR 86 (86) 88 (88) 88 (88)
95% CIa 77.6 to 92.1 80.0 to 93.6 80.0 to 93.6
PFS, monthsc
Median 8.2 9.3 8.6
95% CId 7.4 to 9.7 5.6 to 9.7 7.1 to 9.7
Patients with events 62 (62) 56 (56) 58 (58)
PD 47 (47) 42 (42) 43 (43)
Death 15 (15) 14 (14) 15 (15)
PFS rate, %c
6 months 66.8 59.9 64.0
95% CIe 56.3 to 75.4 49.3 to 69.0 53.4 to 72.8
12 months 30.8 26.4 27.4
95% CIe 20.2 to 42.0 14.9 to 39.3 16.4 to 39.6
TTP, monthsc
Median 9.7 9.7 9.7
95% CId 7.7 to 13.9 7.9 to 11.8 7.7 to 13.9
OS, monthsc
Median 22.0
95% CId 20.4 to NE
Death 34 (34)
(continued on following page)
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Safety
No DLTs were reported in the 6 patients enrolled in the DLT
phase of the study. In the first-line setting, most patients
(99%) experienced an AE (the most common AEs are
reported in Appendix Table A3, online only), and 95% of
patients experienced $ 1 treatment-related AE. The most
common any-grade treatment-related AEs (Table 2) were
hypertension (36%), diarrhea (35%), fatigue (30%), de-
creased appetite (28%), and hypothyroidism (25%). Grade
$ 3 treatment-related AEs occurred in 67% of patients
(grade 3, 63% [n 5 63]; grade 4, 1% [n 5 1]; grade 5,
3% [n 5 3]). The most common grade 3 treatment-related
AE was hypertension (17%). Leukopenia/neutropenia was
the only grade 4 treatment-related AE.
Serious AEs (SAEs) were reported in 65 patients (65%);
treatment-related SAEs were reported in 36 patients (36%).
During the study, 13 (13%) grade 5 AEs occurred: 10
deaths were considered unrelated to study treatment, and
3 deaths were considered treatment related (acute re-
spiratory failure/acute respiratory distress syndrome [n5 1]
on day 124; abnormal hepatic function [n5 1] on day 127;
and intestinal perforation [n 5 1] on day 60).
Treatment-related AEs led to treatment interruption, dose
reduction, and treatment discontinuation of lenvatinib in 62
(62%), 52 (52%), and 14 patients (14%), respectively;
treatment-related AEs led to treatment interruption and
treatment discontinuation of pembrolizumab in 43 (43%)
and 10 patients (10%), respectively. Discontinuation of
both lenvatinib and pembrolizumab because of treatment-
related AEs occurred in 6 patients (6%).
Efficacy
Efficacy data according to investigator assessment by
mRECIST, IIR by mRECIST, and IIR by RECIST v1.1 are
summarized in Table 3. The following results for tumor
assessments (among patients treated in the first-line
setting) are based on IIR. Median duration of follow-up was
10.6 months (95% CI, 9.2 to 11.5 months). ORR (including
confirmed responses only) was 46.0% (95% CI, 36.0% to
56.3%) by mRECIST and 36.0% (95% CI, 26.6% to
46.2%) by RECIST v1.1. CRs (as best overall response)
were observed in 11 patients (11%) by mRECIST and 1
patient (1%) by RECIST v1.1. Median DOR for confirmed
responders was 8.6 months (95% CI, 6.9 months to not
estimable [NE]) by mRECIST and 12.6 months (95% CI,
6.9months to NE) by RECIST v1.1 (Appendix Fig A1, online
only). ORRs were consistent across various subgroups,
including those with poor prognostic features, such as
ECOG PS of 1, macroscopic portal vein invasion, high alpha
fetoprotein level, and BCLC stage C (Appendix Table A4,
online only). Median TTR for confirmed responders was
1.9 months by mRECIST and 2.8 months by RECIST v1.1
(Table 3). Median PFS was 9.3 months (95% CI, 5.6 to 9.7
months) by mRECIST (Table 3; Fig 1A) and 8.6 months by
RECIST v1.1 (95% CI, 7.1 to 9.7 months; Table 3; Fig 1B).
Median OS was 22.0 months (95% CI, 20.4 months to NE;
Table 3; Fig 1C). Reductions in tumor size per IIR by
mRECIST and RECIST v1.1 were reported in 89% (83 of
93) and 83% (78 of 94) of evaluable patients, respectively
(Fig 2), and the reductions seemed to be durable (Fig 3;
Appendix Fig A2, online only). Median TTP was 9.7 months
(95% CI, 7.9 to 11.8 months) by mRECIST per IIR and
9.7 months (95% CI, 7.7 to 13.9 months) by RECIST v1.1
per IIR (Table 3; Appendix Fig A3, online only).
DISCUSSION
Treatment options for advanced HCC have rapidly evolved
over the past several years. After a decade with sorafenib as
the only available treatment in advanced disease, new
options are now available to treat patients in various settings
(eg, first and second lines).3,28 Although single-agent immune
checkpoint inhibitors have demonstrated long-term dis-
ease control with manageable toxicity in a subset of
TABLE 3. Summary of Efficacy Outcomes in Those Receiving Lenvatinib Plus Pembrolizumab (N 5 100) (continued)
Parameter
mRECIST
RECIST Version 1.1 per IIRInvestigator Review IIR
OS rate, %c
6 months 81.0
95% CIe 71.8 to 87.4
12 months 67.5
95% CIe 56.5 to 76.3
NOTE. Data presented as No. (%) unless otherwise indicated.
Abbreviations: CR, complete response; DCR, disease control rate; DOR, duration of response; IIR, independent imaging review; mRECIST,
modified RECIST; NE, not estimable; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival;
PR, partial response; SD, stable disease; TTP, time to progression; TTR, time to response.
aCalculated using exact method of binomial distribution (Clopper-Pearson method).
bIncludes unconfirmed PR, non-CR/non-PD, and durable SD.
cKaplan-Meier method was used for estimating DOR, PFS, TTP, and OS.
dBased on generalized Brookmeyer and Crowley method.
eBased on Greenwood formula using log-log transformation.
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patients,12,13 phase III studies have failed to meet their
primary end points in the first-line setting versus sorafenib29
and second-line setting versus placebo.18
In this phase Ib single-arm study of 100 patients in the first-
line setting, lenvatinib plus pembrolizumab yielded con-
firmed response rates (46% by mRECIST; 36% by RECIST
v1.1) per IIR, median PFS of 9.3 months (by mRECIST;
8.6 months by RECIST v1.1) per IIR, and median OS of
22.0 months. Moreover, responses were durable (median
DOR, 8.6months bymRECIST and 12.6months by RECIST
v1.1) per IIR. Together, these numbers indicate that
multikinase inhibition (ie, VEGF receptors 1-3, FGF re-
ceptors 1-4, PDGFRa, RET, and KIT)6-9 with lenvatinib plus
PD-1 inhibition with pembrolizumab results in improved
antitumor activity. Although the exact mechanism driving
these higher response rates is still not well understood,
preclinical data suggest that the immunomodulatory effect
of lenvatinib complements pembrolizumab activity, thereby
increasing sensitivity of tumors to this combination
therapy.24,25 Similar observations have been described in
other immune checkpoint inhibitor combination studies in
advanced HCC. In the phase III IMbrave150 study,30
atezolizumab (a PD-L1 antibody) plus bevacizumab (a
VEGF inhibitor) treatment resulted in improved OS compared
with sorafenib (HR, 0.58; 95% CI, 0.42 to 0.79; P5 .0006),
as well as response rates (ORR and disease control rate
[DCR]) . 27% per RECIST v1.1. This combination is now
included in the National Comprehensive Cancer Network
guidelines for hepatobiliary cancer.32 Moreover, ipilimu-
mab (a CTLA-4 antibody) plus nivolumab (a PD-1 antibody)
as second-line agents for HCC33 had response rates (ORR
and DCR) . 30% by RECIST v1.1. Similar to outcomes
reported with lenvatinib plus pembrolizumab, these com-
binations yielded durable responses.
In this study, with patients who had uHCC but well-
preserved liver function, there were no new or un-
expected toxicities resulting from lenvatinib plus pem-
brolizumab combination therapy. Treatment-related AEs
with the combination of lenvatinib and pembrolizumab
were consistent with the known AEs of each individual
agent,10,17,34 and there have been no reported cases of viral
hepatitis flares with pembrolizumab to date.17,18 The most
frequent any-grade treatment-related AEs were hyperten-
sion, diarrhea, fatigue, decreased appetite, and hypothy-
roidism; however, only grade 3 hypertension and elevated
AST occurred in . 10% of patients, and the only grade 4
treatment-related AE was leukopenia/neutropenia (1%).
There were 3 deaths (each occurred early during the study)
Median, 9.3 months 
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FIG 1. Kaplan-Meier estimates of (A) progression-free survival (PFS) by modified RECIST per independent imaging review (IIR), (B) PFS by RECIST
version 1.1 per IIR, and (C) overall survival (OS; efficacy analysis set). NE, not estimable.
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FIG 2. Percentage change from baseline in sums of diameters of target lesions by (A)modified RECIST (mRECIST) per independent imaging
review (IIR), (B) mRECIST per investigator review, and (C) RECIST version 1.1 per IIR. CR, complete response; HCC-1L, hepatocellular
carcinoma first line; NE, not estimable; PD, progressive disease; PR, partial response; SD, stable disease. (a) Unconfirmed PR. (b) Non-CR/
non-PD. (c) No. of patients with both baseline and postbaseline sums of diameters of target lesions.
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considered to be treatment related by the investigator,
attributed to acute respiratory failure/acute respiratory
distress syndrome (n5 1), abnormal hepatic function (n5
1), and intestinal perforation (n 5 1), all of which are well-
described potential AEs for these drug classes. Overall,
treatment-related AEs led to discontinuation of both lenva-
tinib and pembrolizumab in 6 patients (6%). These rates
were comparable to those reported in monotherapy studies
of each drug in patients with HCC, suggesting that the toxicity
profile of this combination is manageable with appropriate
monitoring, treatment interruption, and/or dose modification
(this latter option applies to lenvatinib only).10,17,18,34
Lenvatinib plus pembrolizumab resulted in a DCR of
. 85% (irrespective of RECIST category) in this study,
but further refinement of the population selection criteria
to target those most likely to benefit from this combina-
tion therapy would be valuable. To date, serum and
tissue biomarker analyses of patients with advanced HCC
who were treated with either lenvatinib35 or checkpoint
inhibitors17,18,36 have not clearly defined predictive markers
of response or resistance. Importantly, in this current study,
efforts were made to collect archival tumor tissue or a newly
obtained biopsy before the first dose of study drug in the
expansion phase, and these tissue samples will provide
analytic material for future mechanism-based biomarker
analyses.
Despite recent advances in treatment, advanced HCC is
still associated with poor prognosis andmedian OS remains
approximately 1 year.3 The competing risk of death from
both underlying liver disease and malignancy adds sig-
nificant complexity to the clinical management of these
patients because AEs must be balanced with efficacy.
Median OS and TTP for approved first-line treatments, such
as sorafenib and lenvatinib, range from 11 to 14 and 4 to 9
months, respectively.3,4,10 Although most agents available
to treat advanced HCC have improved survival, response
rates remain low.28 ORR rates after lenvatinib and sorafenib


































































FIG 3. Percentage change from
baseline in sums of diameters of tar-
get lesions by (A) modified RECIST per
independent imaging review (IIR)
and (B) RECIST version 1.1 per IIR. (a)
Value (127.8%) beyond y-axis limit is
truncated and not displayed.
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respectively.10 In this study of lenvatinib plus pembrolizumab,
improvements in both ORR and DCR were observed.
The current data are limited because of the nature of this
study (ie, single arm and open label). However, the sample
size, multicenter design, and AE profile of the study and its use
of blinded IIR support the conclusion that lenvatinib plus
pembrolizumab demonstrated promising antitumor activity
with acceptable tolerability. Moreover, on the basis of interim
data from this study, the FDA granted lenvatinib plus pem-
brolizumab a breakthrough therapy designation for the first-line
treatment of uHCC that is not amenable to locoregional ther-
apy. An ongoing double-blind randomized controlled phase III
study of lenvatinib plus pembrolizumab versus lenvatinib plus
placebo as first-line treatment of uHCC (LEAP-002; Clinical-
Trials.gov identifier: NCT03713593) should confirm the effi-
cacy and safety of this combination in patients with uHCC.
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APPENDIX Pembrolizumab Treatment
Patients who stopped study treatment after receiving 35 administra-
tions of pembrolizumab for reasons other than progressive disease or
intolerability and patients who achieved a complete response and
stopped study treatment were eligible to receive a second course of
treatment of up to 17 additional administrations of pembrolizumab
(approximately 1 year).
Tumor Responses
As of February 2018, all tumor assessment scans (including scans
previously reviewed by investigators) were sent to an imaging core
laboratory for independent imaging review by RECIST version 1.1 and
modified RECIST. Tumor assessments of complete or partial response
were confirmed $ 4 weeks after initial response.
Expansion of Enrollment and Sample Size Determination
A protocol amendment allowed for the expansion phase to be further
expanded by approximately 94 evaluable patients. Interim analyses
were planned to take place when 20 (6 patients for the DLT phase plus
14 patients for the expansion phase) and 56 patients (6 patients for the
DLT phase plus 50 patients for the expansion phase) had sufficient
follow-up to be evaluated for response. The decision to expand
enrollment was based on the results of these 2 interim analyses, which
spent b 5 0.012 and b 5 0.024 at the first and second interim
analyses, respectively.
On the basis of an assumption of H0: 25% objective response rate
(ORR) and H1: 45% ORR, the 100-patient design with 2 futility an-
alyses had approximately 96% statistical power at 2-sided a 5 0.02
(corresponding to 1-sided a 5 0.01). At the first interim analysis (n 5
20), if there were. 5 responses, approximately 36 additional patients
would be enrolled. At the second interim analysis (n 5 56), if there
were . 16 responses, approximately 44 additional patients would be
enrolled. If there were # 5 responses at the first interim analysis (n 5
20) or # 16 responses at the second interim analysis (n 5 56), the
sponsor would decide whether to expand enrollment based on clinical
outcome (eg, duration of response). The 2 interim analyses were not
formally conducted, because the numbers of responses required to
enable expansion enrollment were reached before the planned interim
analyses at n 5 20 and n 5 56, respectively.
Data-Sharing Statement
The data will not be available for sharing at this time, because the data
are commercially confidential. However, Eisai will consider written
requests to share the data on a case-by-case basis.
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FIG A1. Kaplan-Meier estimate of duration of response by (A) modified RECIST and (B) RECIST version 1.1 per
independent imaging review. NE, not estimable.
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FIG A2. Duration of treatment and response assessments by (A) modified RECIST and (B) RECIST version 1.1 per independent imaging review. BOR,
best overall response; CR, complete response; DLT, dose-limiting toxicity; EXP, expansion; NE, not estimable; PD, progressive disease; PR, partial
response; SD, stable disease. (a) Non-CR/non-PD. (b) Unconfirmed PR.
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FIG A3. Kaplan-Meier estimate of time to progression (TTP) by (A) modified RECIST and (B) RECIST version 1.1 per
independent imaging review.
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TABLE A1. Patient Disposition and Reasons for Discontinuation From
Treatment at Data Cutoff Date of October 31, 2019, Among Those
Receiving Lenvatinib Plus Pembrolizumab (N 5 100)
Parameter No. (%)
Treatment ongoing 37 (37)
Both study drugs 34 (34)
Lenvatinib only 3 (3)
Pembrolizumab only 0
Discontinued treatment 63 (63)
Primary reason for discontinuation
Radiologic disease progression 35 (35)
Clinical disease progression 7 (7)
Adverse event 18 (18)
Patient choice 1 (1)
Withdrawal of consent 1 (1)
Othera 1 (1)
Discontinued treatment but in survival follow-up 26 (26)
aNoncompliance with protocol procedures.
TABLE A2. Anticancer Medications During Survival Follow-Up Among
Those Receiving Lenvatinib Plus Pembrolizumab (N 5 100)
Preferred Medication Term No. (%)














Investigational drug 1 (1)
NOTE. Patients with $ 2 medications within a class level and drug
name are counted only once within that class level and drug name.
Abbreviations: FOLFOX, leucovorin, fluorouracil, and oxaliplatin.
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TABLE A3. Most Common Treatment-Emergent AEs Among Those Receiving Lenvatinib Plus Pembrolizumab (N 5 100)
Preferred AE Terma
No. (%)
Any Gradeb Grade 1 Grade 2 Grade 3 Grade ‡ 4
Diarrhea 50 (50) 29 (29) 14 (14) 7 (7) 0
Hypertension 38 (38) 2 (2) 18 (18) 18 (18) 0
Decreased appetite 36 (36) 16 (16) 19 (19) 1 (1) 0
Fatigue 33 (33) 13 (13) 14 (14) 6 (6) 0
Hypothyroidism 31 (31) 15 (15) 16 (16) 0 0
AST level increased 30 (30) 8 (8) 8 (8) 14 (14) 0
Weight decreased 30 (30) 10 (10) 15 (15) 5 (5) 0
Proteinuria 25 (25) 9 (9) 11 (11) 5 (5) 0
Asthenia 24 (24) 6 (6) 12 (12) 6 (6) 0
Dysphonia 23 (23) 19 (19) 3 (3) 1 (1) 0
Nausea 23 (23) 13 (13) 7 (7) 3 (3) 0
Palmar-plantar erythrodysesthesia syndrome 23 (23) 13 (13) 9 (9) 1 (1) 0
Anemia 21 (21) 10 (10) 7 (7) 4 (4) 0
Abdominal pain 20 (20) 11 (11) 5 (5) 4 (4) 0
Blood bilirubin level increased 20 (20) 2 (2) 10 (10) 6 (6) 2 (2)
Lipase increased 20 (20) 5 (5) 4 (4) 11 (11) 0
ALT level increased 19 (19) 9 (9) 4 (4) 6 (6) 0
Vomiting 19 (19) 13 (13) 3 (3) 3 (3) 0
Pruritus 17 (17) 15 (15) 2 (2) 0 0
Rash 17 (17) 13 (13) 3 (3) 1 (1) 0
Arthralgia 16 (16) 12 (12) 4 (4) 0 0
Edema peripheral 16 (16) 11 (11) 5 (5) 0 0
Hypoalbuminemia 15 (15) 2 (2) 12 (12) 1 (1) 0
Stomatitis 15 (15) 7 (7) 4 (4) 4 (4) 0
NOTE. Any-grade treatment-emergent adverse events (AEs) occurring in $ 15% of patients.
aPatient with$ 2 treatment-emergent AEs reported in the same preferred term is only counted once using the highest Common Terminology
Criteria for Adverse Events grade.
bPatients may have experienced multiple AEs per Common Terminology Criteria for Adverse Events grade. Grade 4 treatment-emergent AEs
occurred in 10 patients and included thrombocytopenia (n5 1), neutropenia (n5 2), leukopenia (n5 1), pancytopenia (n5 1), general physical
health deterioration (n5 1), hyperbilirubinemia (n5 1), sepsis (n5 1), biliary sepsis (n5 1), endocarditis (n5 1), WBC count decreased (n5
1), neutrophil count decreased (n5 1), blood bilirubin increased (n5 2), hyperkalemia (n5 1), hypertriglyceridemia (n5 1), acute lymphocytic
leukemia (n5 1), pancreatic carcinoma (n5 1), and hepatic encephalopathy (n5 1). Grade 5 treatment-emergent AEs occurred in 13 patients
and included abnormal hepatic function (n5 1), pneumonia (n5 1), death (n5 2), hepatic failure (n5 2), hepatic cirrhosis (n5 1), sepsis (n5
1), upper GI hemorrhage (n 5 1), myocardial infarction (n 5 1), intestinal perforation (n 5 1), bacterial peritonitis (n 5 1), acute respiratory
distress syndrome (n 5 1), and acute respiratory failure (n 5 1).
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ORR (IIR; RECIST v1.1) 36 (36.0) 23 (37.1) 13 (34.2) 6 (37.5) 30 (35.7) 21 (34.4) 15 (41.7) 12 (41.4) 24 (33.8)
95% CI 26.6 to 46.2 25.2 to 50.3 19.6 to 51.4 15.2 to 64.6 25.6 to 46.9 22.7 to 47.7 25.5 to 59.2 23.5 to 61.1 23.0 to 46.0
ORR (IIR; mRECIST) 46 (46.0) 30 (48.4) 16 (42.1) 5 (31.3) 41 (48.8) 27 (44.3) 17 (47.2) 15 (51.7) 31 (43.7)
95% CI 36.0 to 56.3 35.5 to 61.4 26.3 to 59.2 11.0 to 58.7 37.7 to 60.0 31.5 to 57.6 30.4 to 64.5 32.5 to 70.6 31.9 to 56.0
Abbreviations: AFP, alpha fetoprotein; BCLC, Barcelona Clinic Liver Cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; IIR,
independent imaging review; MPVI, macroscopic portal vein invasion; mRECIST, modified RECIST; ORR, objective response rate.
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